Cory Renauer
Value, research analyst, biotech, small-cap

InterMune Successfully Entering Huge Niche Market Unchallenged

InterMune (NASDAQ:ITMN) is a not yet profitable biotech based in Brisbane, California. The company is heavily invested in the development of orally delivered, Esbriet (pirfenidone). In February 2011, Esbriet was granted marketing authorization in all 27 EU countries for the treatment of idiopathic pulmonary fibrosis [IPF], an orphan indication with a relatively large patient base.

A glaring unmet need

IPF is a chronic, progressive, and fatal disease with an unknown cause characterized by the formation of excess fibrous connective tissue, or fibrosis, of the lungs' supporting framework. The disease progresses rapidly, and the median survival time from diagnosis is just two to five years. The five year survival rate is between 20-40 percent. Currently, Esbriet is the only...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details